From OncLive, five experts share their perspectives and opinions on the latest research related to triple-negative breast cancer.
Participants include Joyce A. O'Shaughnessy, MD, Baylor-Sammons Cancer Center; Adam M. Brufsky, MD, University of Pittsburg Cancer Institute; Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center; Kevin M. Kalinsky, MD, Columbia University Medical Center; and Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute.
The experts discuss new data from the European Society for Medical Oncology’s (ESMO) Virtual Congress 2020 and standards of care for early-stage triple-negative breast cancer.
“I think that increasingly for our patients with early-stage triple-negative breast cancer, we treat with neoadjuvant chemotherapy. I think that this is for a number of reasons so that we could see how patients are responding to the treatments that we’re giving,” said Dr. Kalinsky.
Visit OncLive to hear their perspectives.
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.